^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    carfilzomib

    i
    Other names: PR-171, ONO 7057, ONO-7057, ONO7057, PR171, PR 171
    Company:
    Generic mfg.
    Drug class:
    Proteasome inhibitor
    Related drugs:
    3d
    Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=75 --> 17
    Enrollment closed • Enrollment change
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    lenalidomide • carfilzomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets) • dexamethasone injection
    5d
    Causal Effects of Hydrophilic Bile Acids on Carfilzomib-Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study. (PubMed, Clin Pharmacol Ther)
    Gene enrichment analysis indicated pathways involving potassium channel regulation and thromboxane signaling to be implicated. This integrative metabolomic and genetic investigation supports a potential protective role of glycoursodeoxycholic acid in cardiovascular vulnerability and motivates larger, carfilzomib-specific studies to evaluate its utility for risk stratification.
    Journal
    |
    NPPB (Natriuretic Peptide B)
    |
    carfilzomib
    9d
    Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    carboplatin • Rituxan (rituximab) • cyclophosphamide • ifosfamide • etoposide IV • carfilzomib • Truxima (rituximab-abbs)
    15d
    Molecular mechanisms of aquaporin 1 inhibition by Bacopaside I and Bacopaside II: Insights from molecular dynamics simulations. (PubMed, J Mol Graph Model)
    Energy decomposition analysis identifies key interacting residues Pro171, Ile174, and Ala66 that anchor the inhibitors. Although both ligands induce subtle constriction of the channel pores, Bacopaside II establishes a more persistent hydrogen bonding network, underscoring its unique energetic contribution to the inhibition profile. Overall, these findings provide a detailed mechanistic blueprint for AQP1 inhibition by Bacopasides and offer a structural framework for the rational design of next-generation AQP1-targeted anticancer therapies.
    Journal
    |
    AQP1 (Aquaporin 1)
    |
    carfilzomib
    16d
    CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    carfilzomib • telaglenastat (CB-839) • Hemady (dexamethasone tablets)
    17d
    LINKER-MM5: A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=915, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    bortezomib • carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Lynozyfic (linvoseltamab-gcpt)
    21d
    Mezi-KD: A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    New P2 trial
    |
    carfilzomib • mezigdomide (CC-92480)
    21d
    Elo-KRd: Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma (clinicaltrials.gov)
    P2, N=46, Completed, University of Chicago | Trial completion date: Mar 2027 --> Dec 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    lenalidomide • carfilzomib • Empliciti (elotuzumab)
    25d
    Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease (clinicaltrials.gov)
    P2, N=28, Recruiting, Roswell Park Cancer Institute | Suspended --> Recruiting
    Enrollment open
    |
    carfilzomib • mezigdomide (CC-92480)
    28d
    KTX-MMSET-001: A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=125, Recruiting, K36 Therapeutics, Inc. | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    carfilzomib • pomalidomide • mezigdomide (CC-92480) • gintemetostat (KTX-1001)
    29d
    A Study of NINLARO® in Chinese Adults With Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=72, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    bortezomib • Ninlaro (ixazomib) • carfilzomib
    2ms
    IZALCO: A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carfilzomib • dexamethasone injection • isatuximab subcutaneous (SAR650984 SC)